AEON Biopharma (AEON) Profit After Tax (2021 - 2026)

AEON Biopharma has reported Profit After Tax for 5 years, with the latest figure at -$37.1 million in Q4 2025.

• Quarterly Profit After Tax fell 1883.72% year-over-year to -$37.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$39.2 million (down 193.37% YoY) and the FY2025 annual result came in at -$39.2 million, down 193.37% from the prior year.
• Profit After Tax declined to -$37.1 million in Q4 2025 per AEON's latest filing, from -$4.5 million in the prior quarter.
• Over five years, Profit After Tax peaked at $164.1 million in Q2 2024 and troughed at -$297.7 million in Q3 2023.
• A 5-year average of -$15.0 million and a median of $92389.0 in 2022 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 4262.81% in 2024, down 30276.69% in 2024.
• Over 5 years, Profit After Tax stood at $247874.0 in 2021, then plunged by 62.73% to $92389.0 in 2022, then slumped by 322336.41% to -$297.7 million in 2023, then jumped by 100.7% to $2.1 million in 2024, then plunged by 1883.72% to -$37.1 million in 2025.
• According to Business Quant data, Profit After Tax over the past three periods registered -$37.1 million, -$4.5 million, and -$6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.